FDA Accepts Mesoblast’s Resubmission of the Biologic License Application for Remestemcel-L In Children with Steroid-Refractory Acute Graft Versus Host Disease as a Complete Response and Sets Goal Date of August 2, 2023Mar 8, 2023
FDA Accepts Mesoblast’s Resubmission of the Biologic License Application for Remestemcel-L In Children with Steroid-Refractory Acute Graft Versus Host Disease as a Complete Response and Sets Goal Date of August 2, 2023Mar 8, 2023
Coronary Artery Bypass Graft Surgery Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2023 UpdateFeb 28, 2023
Bone Graft Substitute Market Size to Hit USD 2121.66 Million by 2030 at 6.80% CAGR – Report by Market Research Future (MRFR)Feb 13, 2023